Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide dose-escalation study in dumping syndrome
2012-001534-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in dumping syndrome, sponsored by Novartis. Primary endpoint: Response rate in plasma glucose level at the end of subcutaneous dose escalation phase. Started Jul 2012; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
dumping syndrome
Beyond the preview
Go deeper on 2012-001534-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001534-34.